Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy

Background: Radiodermatitis is a frequent side effect of breast cancer radiotherapy (RT). Treating radiation oncologist should know the prevention and treatment of every grade of radiodermatitis. Aims: The aim of this study was to compare the topical corticosteroid and moisturizer usage in breast ca...

Full description

Bibliographic Details
Main Authors: Bora Uysal, Hakan Gamsız, Ferrat Dincoglan, Selcuk Demiral, Omer Sager, Bahar Dirican, Murat Beyzadeoglu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Indian Journal of Dermatology
Subjects:
Online Access:http://www.e-ijd.org/article.asp?issn=0019-5154;year=2020;volume=65;issue=4;spage=279;epage=283;aulast=Uysal
_version_ 1819000538376699904
author Bora Uysal
Hakan Gamsız
Ferrat Dincoglan
Selcuk Demiral
Omer Sager
Bahar Dirican
Murat Beyzadeoglu
author_facet Bora Uysal
Hakan Gamsız
Ferrat Dincoglan
Selcuk Demiral
Omer Sager
Bahar Dirican
Murat Beyzadeoglu
author_sort Bora Uysal
collection DOAJ
description Background: Radiodermatitis is a frequent side effect of breast cancer radiotherapy (RT). Treating radiation oncologist should know the prevention and treatment of every grade of radiodermatitis. Aims: The aim of this study was to compare the topical corticosteroid and moisturizer usage in breast cancer RT. Materials and Methods: Fifty patients with early-stage breast cancer undergoing breast-conserving surgery referred to our department for adjuvant RT between October 2009 and October 2016 were compared with regard to topical steroid or moisturizer usage. Patients were followed up weekly after the start of treatment. Results: Mean age was 46 years. Twenty-four patients had stage 1 breast cancer and 26 patients had stage 2 disease. KPS (Karnofsky performance score) was 100 for all patients. Five patients (20.8%) had grade 2 and seven (29.1%) patients had grade 1 acute radiodermatitis in the first group. Eleven (42.3%) patients had grade 2 and 12 (46.1%) patients had grade 1 acute radiodermatitis in the second group. Thirteen (54.1%) patients in the first group had no acute radiodermatitis and three (11.5%) patients in the second group had no acute radiodermatitis. No patient in either group experienced grade 3 radiodermatitis. Conclusions: Daily use of topical betamethasone for breast cancer RT improves dermal sparing, reduces acute radiodermatitis, and may be recommended for patients receiving RT to the breast.
first_indexed 2024-12-20T22:34:54Z
format Article
id doaj.art-700476bcad81447ea6c7eec32950617c
institution Directory Open Access Journal
issn 0019-5154
1998-3611
language English
last_indexed 2024-12-20T22:34:54Z
publishDate 2020-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Dermatology
spelling doaj.art-700476bcad81447ea6c7eec32950617c2022-12-21T19:24:38ZengWolters Kluwer Medknow PublicationsIndian Journal of Dermatology0019-51541998-36112020-01-0165427928310.4103/ijd.IJD_607_18Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapyBora UysalHakan GamsızFerrat DincoglanSelcuk DemiralOmer SagerBahar DiricanMurat BeyzadeogluBackground: Radiodermatitis is a frequent side effect of breast cancer radiotherapy (RT). Treating radiation oncologist should know the prevention and treatment of every grade of radiodermatitis. Aims: The aim of this study was to compare the topical corticosteroid and moisturizer usage in breast cancer RT. Materials and Methods: Fifty patients with early-stage breast cancer undergoing breast-conserving surgery referred to our department for adjuvant RT between October 2009 and October 2016 were compared with regard to topical steroid or moisturizer usage. Patients were followed up weekly after the start of treatment. Results: Mean age was 46 years. Twenty-four patients had stage 1 breast cancer and 26 patients had stage 2 disease. KPS (Karnofsky performance score) was 100 for all patients. Five patients (20.8%) had grade 2 and seven (29.1%) patients had grade 1 acute radiodermatitis in the first group. Eleven (42.3%) patients had grade 2 and 12 (46.1%) patients had grade 1 acute radiodermatitis in the second group. Thirteen (54.1%) patients in the first group had no acute radiodermatitis and three (11.5%) patients in the second group had no acute radiodermatitis. No patient in either group experienced grade 3 radiodermatitis. Conclusions: Daily use of topical betamethasone for breast cancer RT improves dermal sparing, reduces acute radiodermatitis, and may be recommended for patients receiving RT to the breast.http://www.e-ijd.org/article.asp?issn=0019-5154;year=2020;volume=65;issue=4;spage=279;epage=283;aulast=Uysalbreast cancermoisturizerradiotherapytopical steroid
spellingShingle Bora Uysal
Hakan Gamsız
Ferrat Dincoglan
Selcuk Demiral
Omer Sager
Bahar Dirican
Murat Beyzadeoglu
Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy
Indian Journal of Dermatology
breast cancer
moisturizer
radiotherapy
topical steroid
title Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy
title_full Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy
title_fullStr Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy
title_full_unstemmed Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy
title_short Comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy
title_sort comparative evaluation of topical corticosteroid and moisturizer in the prevention of radiodermatitis in breast cancer radiotherapy
topic breast cancer
moisturizer
radiotherapy
topical steroid
url http://www.e-ijd.org/article.asp?issn=0019-5154;year=2020;volume=65;issue=4;spage=279;epage=283;aulast=Uysal
work_keys_str_mv AT borauysal comparativeevaluationoftopicalcorticosteroidandmoisturizerinthepreventionofradiodermatitisinbreastcancerradiotherapy
AT hakangamsız comparativeevaluationoftopicalcorticosteroidandmoisturizerinthepreventionofradiodermatitisinbreastcancerradiotherapy
AT ferratdincoglan comparativeevaluationoftopicalcorticosteroidandmoisturizerinthepreventionofradiodermatitisinbreastcancerradiotherapy
AT selcukdemiral comparativeevaluationoftopicalcorticosteroidandmoisturizerinthepreventionofradiodermatitisinbreastcancerradiotherapy
AT omersager comparativeevaluationoftopicalcorticosteroidandmoisturizerinthepreventionofradiodermatitisinbreastcancerradiotherapy
AT bahardirican comparativeevaluationoftopicalcorticosteroidandmoisturizerinthepreventionofradiodermatitisinbreastcancerradiotherapy
AT muratbeyzadeoglu comparativeevaluationoftopicalcorticosteroidandmoisturizerinthepreventionofradiodermatitisinbreastcancerradiotherapy